
An mRNA cancer vaccine may offer long-term protection
In a small clinical trial involving pancreatic cancer patients, the vaccine spurred a strong immune response in eight out of 16 participants, generating a legion of red flag–targeting T cells.
In a small clinical trial involving pancreatic cancer patients, the vaccine spurred a strong immune response in eight out of 16 participants, generating a legion of red flag–targeting T cells.
In a large study in Sweden, people who inherited two copies of the spread-associated variant have a 22 percent risk of developing metastasis within 15 years of their original diagnosis, the researchers found.